Recursion Pharmaceuticals, Inc.
RXRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Recursion Pharmaceuticals, Inc. focuses on Biotechnology services and products. Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation,. Valued at $1.98B, RXRX is a small-cap name in its sector. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Market Cap
$1.98B
Beta
1.03
P/E (TTM)
—
P/E (Fwd)
-4.25
EPS (TTM)
$-1.00
EPS (Fwd)
$-0.87
ROE
-56.6%
ROA
-27.3%
Cash
$545.7M
Total Debt
$66.6M
Free CF
-$219.5M
52W Change
-41.3%
Annual Financials
Cash vs Debt
Where RXRX stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, RXRX finished 10.00% above its 150-day moving average ($3.40) and 4.76% above its 200-day moving average ($3.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RXRX overbought or oversold?
At the October 15, 2026 close, RXRX's RSI(14) was 47.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Recursion Pharmaceuticals, Inc. holds $545.7M in cash against $66.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$219.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -56.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $39.7M (2022) to $74.3M (2025), reflecting a 87% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing RXRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.